Therapeutic Strategy for BRAF-Mutated Cancer

Research output: Contribution to journalArticlepeer-review

Abstract

BRAF mutation is occurred in about 8% of human malignancy, including 40-60% in malignant melanoma, 50% in thyroid papillary cancer, 10% in colorectal cancer, and a few percent of non-small cell lung cancer. Activated mutation of BRAF is mainly p. V600E mutation. BRAF inhibitors were initially developed in malignant melanoma. In a recent few years, BRAF inhibitor-based therapy has been developed also in other cancers such as lung cancer and colorectal cancer. I herein describe the current status of development of new therapeutic strategies for S/MF-mutated cancer, particularly BRAF-targeting therapy.

Original languageEnglish
Pages (from-to)861-865
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume48
Issue number7
Publication statusPublished - 2021 Jul

Keywords

  • Anti-EGFR-antibody
  • BRAF inhibitor
  • BRAF mutation
  • MEK inhibitor

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Therapeutic Strategy for BRAF-Mutated Cancer'. Together they form a unique fingerprint.

Cite this